Patrick Grace
This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will receive rapid testing and, if eligible, hepatitis C medication before leaving the emergency department. The study will also use a smart pillbox, an AI-powered virtual agent, and community health worker support to help participants take their medication as prescribed. Participants will have follow-up visits and testing to assess medication adherence and whether the hepatitis C infection is cured.
Inclusion Criteria: * Age 22-65 years old, presenting to the Emergency Department (ED) who are undergoing antibody testing as part of universal screening * Patients to be discharged from the ED or ED Observational units Exclusion Criteria: * Capacity to Consent * Emergency Severity Index (ESI) Level one (high acuity patients) * Known noninvasive serologic tests above proprietary cutoffs indicating cirrhosis (example - FibroSure, Enhanced Liver Fibrosis Test, etc.) * Known clinical evidence of cirrhosis (egliver nodularity and/or splenomegaly on imaging, platelet count \<150,000/m3, etc.) *…
Participants who test positive for hepatitis C will receive sofosbuvir/velpatasvir treatment before discharge from the Emergency Department. The first month of medication will be provided by the study, with subsequent treatment coordinated through the clinical team and specialty pharmacy.
Arctuva estimate
Verify or correct the compensation shown for this listing.